Huadong Medicine Co., Ltd.
Huadong Medicine is a Hangzhou-based pharmaceutical group listed in Shenzhen (SZSE: 000963), active in oncology, metabolism and immunology. Its oral GLP-1 candidate conveglipron (HDM1002) is in Phase 3 in China.
| Headquarters | Hangzhou, China |
|---|---|
| Listing | SZSE:000963 |
| Lead asset / stage | conveglipron (HDM1002) Phase 3 — China |
| Latest event | Doer Biologics received China IND approval for a new indication of DR30206 injection. |